The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro-Reference-Cited by-同舟云学术

The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro

Published:2020-10 Issue: Volume:182 Page:104902
ISSN:0166-3542
Container-title:Antiviral Research
language:en
Short-container-title:Antiviral Research

Author:

Okamoto Mika,Toyama Masaaki,Baba Masanori^ORCID

Publisher

Elsevier BV

Subject

Virology,Pharmacology

Reference24 articles.

1. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: a comprehensive review;Alijotas-Reiga;Autoimmun. Rev.,2020

2. TAK-652 inhibits CCR5-mediated human immunodeficiency virustype 1 infection in vitro and has favorable pharmacokinetics in humans;Baba;Antimicrob. Agents Chemother.,2005

3. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro;Caly;Antivir. Res.,2020

4. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19;Cao;N. Engl. J. Med.,2020

5. Monocyte chemoattractant protein-1 released from alveolar macrophages mediates the systemic inflammation of acute alveolar hypoxia;Chao;Am. J. Respir. Cell Mol. Biol.,2011

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Virus‐Induced Host Chemokine CCL2 in COVID‐19 Pathogenesis: Potential Prognostic Marker and Target of Anti‐Inflammatory Strategy;Reviews in Medical Virology;2024-08-27

2. The role of CCL2/CCR2 axis in cancer and inflammation: The next frontier in nanomedicine;Advanced Drug Delivery Reviews;2024-06

3. Cenicriviroc, a CCR2/CCR5 antagonist, promotes the generation of type 1 regulatory T cells;European Journal of Immunology;2024-04-21

4. CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome;Frontiers in Pharmacology;2024-02-21

5. Chemokine receptors in COVID-19 infection;International Review of Cell and Molecular Biology;2024